Somatostatin analogues are considered first-line therapy in patients with digestive endocrine tumours. Indeed, several studies have investigated their efficacy in the control of specific symptoms and in the decrease of tumour markers. However, randomised controlled trials are needed in order to better define their role in non functioning tumours and their effect on tumour growth, which have seldom been assessed. Several new drugs have been developed over the last few years such as, for example, new long-acting formulations, universal analogues binding to all five somatostatin receptors subtypes, and cytotoxic analogues, all of which offer a promising therapeutic tool in the near future, even if further studies are needed to determine their efficacy and safety in man. (C) 2003 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Unlabelled somatostatin analogues in treatment of digestive endocrine tumours / F., Panzuto; S., Nasoni; F., Baccini; S., Cassetta; Corleto, Vito Domenico; DELLE FAVE, Gianfranco. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 36:1(2004), pp. S42-S47. (Intervento presentato al convegno Meeting on Somatostatin Receptors tenutosi a Borgo Monastero, ITALY nel OCT, 2001) [10.1016/j.dld.2003.11.013].
Unlabelled somatostatin analogues in treatment of digestive endocrine tumours
F. Panzuto;CORLETO, Vito Domenico;DELLE FAVE, Gianfranco
2004
Abstract
Somatostatin analogues are considered first-line therapy in patients with digestive endocrine tumours. Indeed, several studies have investigated their efficacy in the control of specific symptoms and in the decrease of tumour markers. However, randomised controlled trials are needed in order to better define their role in non functioning tumours and their effect on tumour growth, which have seldom been assessed. Several new drugs have been developed over the last few years such as, for example, new long-acting formulations, universal analogues binding to all five somatostatin receptors subtypes, and cytotoxic analogues, all of which offer a promising therapeutic tool in the near future, even if further studies are needed to determine their efficacy and safety in man. (C) 2003 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
